6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
also O
discussed O
elsewhere O
in O
the O
labeling O
: O
* O
Bleeding B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Dyspnea B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
are O
bleeding O
12 O
% O
and O
dyspnea O
14 O
% O
. O

( O
5.1 O
, O
5.3 O
, O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
AstraZeneca O
at O
1-800-236-9933 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

BRILINTA O
has O
been O
evaluated O
for O
safety O
in O
more O
than O
27000 O
patients O
, O
including O
more O
than O
13000 O
patients O
treated O
for O
at O
least O
1 O
year O
. O

Bleeding O
in O
PLATO O
( O
Reduction O
in O
risk O
of O
thrombotic O
events O
in O
ACS O
) O
Figure O
1 O
is O
a O
plot O
of O
time O
to O
the O
first O
non-CABG O
major O
bleeding B-NonOSE_AE
event O
. O

Figure O
1 O
- O
Kaplan-Meier O
estimate O
of O
time O
to O
first O
non-CABG O
PLATO-defined O
major O
bleeding O
event O
( O
PLATO O
) O
Frequency O
of O
bleeding B-NonOSE_AE
in O
PLATO O
is O
summarized O
in O
Tables O
1 O
and O
2 O
. O

About O
half O
of O
the O
Non-CABG O
major O
bleeding B-OSE_Labeled_AE
events O
were O
in O
the O
first O
30 O
days O
. O

Table O
1 O
- O
Non-CABG O
related O
bleeds B-OSE_Labeled_AE
( O
PLATO O
) O
BRILINTA O
N=9235 O
Clopidogrel O
N=9186 O
n O
( O
% O
) O
patients O
with O
event O
n O
( O
% O
) O
patients O
with O
event O
PLATO O
Major O
+ O
Minor O
713 O
( O
7.7 O
) O
567 O
( O
6.2 O
) O
Major O
362 O
( O
3.9 O
) O
306 O
( O
3.3 O
) O
Fatal B-NonOSE_AE
/Life-threatening O
171 O
( O
1.9 O
) O
151 O
( O
1.6 O
) O
Fatal B-NonOSE_AE
15 O
( O
0.2 O
) O
16 O
( O
0.2 O
) O
Intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
( O
Fatal B-NonOSE_AE
/Life-threatening O
) O
26 O
( O
0.3 O
) O
15 O
( O
0.2 O
) O
PLATO O
Minor O
bleed B-OSE_Labeled_AE
: O
requires O
medical O
intervention O
to O
stop O
or O
treat O
bleeding B-NonOSE_AE
. O

PLATO O
Major O
bleed B-OSE_Labeled_AE
: O
any O
one O
of O
the O
following O
: O
fatal O
; O
intracrania O
l B-NonOSE_AE
  I-NonOSE_AE
I I-NonOSE_AE
- I-NonOSE_AE
O I-NonOSE_AE
SE_Labeled_AE O
; O
intrapericardial O
with O
cardiac B-NonOSE_AE
tamponade I-NonOSE_AE
; O
hypovolemic B-NonOSE_AE
shock I-NonOSE_AE
or O
severe B-NonOSE_AE
hypotension I-NonOSE_AE
requiring O
intervention O
; O
significantly O
disabling O
( O
e.g. O
, O
intraocular O
with O
permanent O
vision B-NonOSE_AE
loss I-NonOSE_AE
) O
; O
associated O
with O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
Hb I-NonOSE_AE
of O
at O
least O
3 O
g/dL O
( O
or O
a O
fall B-NonOSE_AE
in I-NonOSE_AE
hematocrit I-NonOSE_AE
( O
Hct O
) O
of O
at O
least O
9 O
% O
) O
; O
transfusion O
of O
2 O
or O
more O
units O
. O

PLATO O
Major O
bleed B-OSE_Labeled_AE
, O
fatal B-NonOSE_AE
/life-threatening O
: O
any O
major O
bleed B-OSE_Labeled_AE
as O
described O
above O
and O
associated O
with O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
Hb I-NonOSE_AE
of O
more O
than O
5 O
g/dL O
( O
or O
a O
fall B-NonOSE_AE
in I-NonOSE_AE
hematocrit I-NonOSE_AE
( O
Hct O
) O
of O
at O
least O
15 O
% O
) O
; O
transfusion O
of O
4 O
or O
more O
units O
. O

Fatal B-NonOSE_AE
: O
A O
bleeding B-OSE_Labeled_AE
event O
that O
directly O
led O
to O
death B-NonOSE_AE
within O
7 O
days O
. O

No O
baseline O
demographic O
factor O
altered O
the O
relative O
risk O
of O
bleeding B-NonOSE_AE
with O
BRILINTA O
compared O
to O
clopidogrel O
. O

In O
PLATO O
, O
1584 O
patients O
underwent O
CABG O
surgery O
. O

The O
percentages O
of O
those O
patients O
who O
bled B-NonOSE_AE
are O
shown O
in O
Figure O
2 O
and O
Table O
2 O
. O

Figure O
2 O
- O
'Major O
fatal/life-threatening O
' O
CABG-related O
bleeding O
by O
days O
from O
last O
dose O
of O
study O
drug O
to O
CABG O
procedure O
( O
PLATO O
) O
X-axis O
is O
days O
from O
last O
dose O
of O
study O
drug O
prior O
to O
CABG O
. O

The O
PLATO O
protocol O
recommended O
a O
procedure O
for O
withholding O
study O
drug O
prior O
to O
CABG O
or O
other O
major O
surgery O
without O
unblinding O
. O

If O
surgery O
was O
elective O
or O
non-urgent O
, O
study O
drug O
was O
interrupted O
temporarily O
, O
as O
follows O
: O
If O
local O
practice O
was O
to O
allow O
antiplatelet O
effects O
to O
dissipate O
before O
surgery O
, O
capsules O
( O
blinded O
clopidogrel O
) O
were O
withheld O
5 O
days O
before O
surgery O
and O
tablets O
( O
blinded O
ticagrelor O
) O
were O
withheld O
for O
a O
minimum O
of O
24 O
hours O
and O
a O
maximum O
of O
72 O
hours O
before O
surgery O
. O

If O
local O
practice O
was O
to O
perform O
surgery O
without O
waiting O
for O
dissipation O
of O
antiplatelet O
effects O
capsules O
and O
tablets O
were O
withheld O
24 O
hours O
prior O
to O
surgery O
and O
use O
of O
aprotinin O
or O
other O
haemostatic O
agents O
was O
allowed O
. O

If O
local O
practice O
was O
to O
use O
IPA O
monitoring O
to O
determine O
when O
surgery O
could O
be O
performed O
both O
the O
capsules O
and O
tablets O
were O
withheld O
at O
the O
same O
time O
and O
the O
usual O
monitoring O
procedures O
followed O
. O

T O
Ticagrelor O
; O
C O
Clopidogrel O
Table O
2 O
- O
CABG-related O
bleeding B-OSE_Labeled_AE
( O
PLATO O
) O
BRILINTA90 O
mg O
BID O
N=770 O
Clopidogrel O
N=814 O
PLATO O
Total O
Major O
626 O
( O
81.3 O
) O
666 O
( O
81.8 O
) O
Fatal B-NonOSE_AE
/Life-threatening O
337 O
( O
43.8 O
) O
350 O
( O
43.0 O
) O
Fatal B-NonOSE_AE
6 O
( O
0.8 O
) O
7 O
( O
0.9 O
) O
PLATO O
Major O
bleed B-OSE_Labeled_AE
: O
any O
one O
of O
the O
following O
: O
fatal O
; O
intracrania O
l B-NonOSE_AE
  I-NonOSE_AE
I I-NonOSE_AE
- I-NonOSE_AE
O I-NonOSE_AE
SE_Labeled_AE O
; O
intrapericardial O
with O
cardiac B-NonOSE_AE
tamponade I-NonOSE_AE
; O
hypovolemic B-NonOSE_AE
shock I-NonOSE_AE
or O
severe B-NonOSE_AE
hypotension I-NonOSE_AE
requiring O
intervention O
; O
significantly O
disabling O
( O
e.g. O
, O
intraocular O
with O
permanent O
vision B-NonOSE_AE
loss I-NonOSE_AE
) O
; O
associated O
with O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
Hb I-NonOSE_AE
of O
at O
least O
3 O
g/dL O
( O
or O
a O
fall B-NonOSE_AE
in I-NonOSE_AE
hematocrit I-NonOSE_AE
( O
Hct O
) O
of O
at O
least O
9 O
% O
) O
; O
transfusion O
of O
2 O
or O
more O
units O
. O

PLATO O
Major O
bleed B-OSE_Labeled_AE
, O
fatal B-NonOSE_AE
/life-threatening O
: O
any O
major O
bleed B-OSE_Labeled_AE
as O
described O
above O
and O
associated O
with O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
Hb I-NonOSE_AE
of O
more O
than O
5 O
g/dL O
( O
or O
a O
fall B-NonOSE_AE
in I-NonOSE_AE
hematocrit I-NonOSE_AE
( O
Hct O
) O
of O
at O
least O
15 O
% O
) O
; O
transfusion O
of O
4 O
or O
more O
units O
. O

When O
antiplatelet O
therapy O
was O
stopped O
5 O
days O
before O
CABG O
, O
major O
bleeding B-OSE_Labeled_AE
occurred O
in O
75 O
% O
of O
BRILINTA O
treated O
patients O
and O
79 O
% O
on O
clopidogrel O
. O

Other O
Adverse O
Reactions O
in O
PLATO O
Adverse O
reactions O
that O
occurred O
at O
a O
rate O
of O
4 O
% O
or O
more O
in O
PLATO O
are O
shown O
in O
Table O
3 O
. O

Table O
3 O
- O
Percentage O
of O
patients O
reporting O
non-hemorrhagic O
adverse O
reactions O
at O
least O
4 O
% O
or O
more O
in O
either O
group O
and O
more O
frequently O
on O
BRILINTA O
( O
PLATO O
) O
BRILINTAN=9235 O
ClopidogrelN=9186 O
Dyspnea B-OSE_Labeled_AE
13.8 O
7.8 O
Dizziness B-OSE_Labeled_AE
4.5 O
3.9 O
Nausea B-OSE_Labeled_AE
4.3 O
3.8 O
Bleeding O
in O
PEGASUS O
( O
Secondary O
Prevention O
in O
Patients O
with O
a O
History O
of O
Myocardial O
Infarction O
) O
Overall O
outcome O
of O
bleeding B-NonOSE_AE
events O
in O
the O
PEGASUS O
study O
are O
shown O
in O
Table O
4 O
. O

Table O
4 O
- O
Bleeding B-OSE_Labeled_AE
events O
( O
PEGASUS O
) O
BRILINTA60 O
mg O
BID O
+ O
Aspirin O
N=6958 O
Aspirin O
Alone O
N=6996 O
n O
( O
% O
) O
patients O
with O
event O
Events O
/100 O
pt O
yrs O
n O
patients O
with O
event O
Events O
/100 O
pt O
yrs O
TIMI O
Major O
115 O
( O
1.7 O
) O
0.78 O
54 O
( O
0.8 O
) O
0.34 O
Fatal B-NonOSE_AE
11 O
( O
0.2 O
) O
0.08 O
12 O
( O
0.2 O
) O
0.08 O
Intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
28 O
( O
0.4 O
) O
0.19 O
23 O
( O
0.3 O
) O
0.14 O
TIMI O
Major O
or O
Minor O
168 O
( O
2.4 O
) O
1.15 O
72 O
( O
1.0 O
) O
0.45 O
TIMI O
Major O
: O
Fatal B-NonOSE_AE
bleeding B-OSE_Labeled_AE
, O
OR O
any O
intracranial B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
OR O
clinically O
overt O
signs O
of O
hemorrhage B-OSE_Labeled_AE
associated O
with O
a O
drop B-NonOSE_AE
in I-NonOSE_AE
hemoglobin I-NonOSE_AE
( I-NonOSE_AE
Hgb I-NonOSE_AE
) O
of O
> O
=5 O
g/dL O
, O
or O
a O
fall B-NonOSE_AE
in I-NonOSE_AE
hematocrit I-NonOSE_AE
( O
Hct O
) O
of O
15 O
% O
. O

Fatal B-NonOSE_AE
: O
A O
bleeding B-OSE_Labeled_AE
event O
that O
directly O
led O
to O
death B-NonOSE_AE
within O
7 O
days O
. O

TIMI O
Minor O
: O
Clinically O
apparent O
with O
3-5 O
g/dL O
decrease B-NonOSE_AE
in I-NonOSE_AE
hemoglobin I-NonOSE_AE
. O

The O
bleeding B-NonOSE_AE
profile O
of O
BRILINTA O
60 O
mg O
compared O
to O
aspirin O
alone O
was O
consistent O
across O
multiple O
pre-defined O
subgroups O
( O
e.g. O
, O
by O
age O
, O
gender O
, O
weight O
, O
race O
, O
geographic O
region O
, O
concurrent O
conditions O
, O
concomitant O
therapy O
, O
stent O
, O
and O
medical O
history O
) O
for O
TIMI O
Major O
and O
TIMI O
Major O
or O
Minor O
bleeding B-NonOSE_AE
events O
. O

Other O
Adverse O
Reactions O
in O
PEGASUS O
Adverse O
reactions O
that O
occurred O
in O
PEGASUS O
at O
rates O
of O
3 O
% O
or O
more O
are O
shown O
in O
Table O
5 O
. O

Table O
5 O
- O
Non-hemorrhagic O
adverse O
reactions O
reported O
in O
> O
3.0 O
% O
of O
patients O
in O
the O
ticagrelor O
60 O
mg O
treatment O
group O
( O
PEGASUS O
) O
BRILINTA O
N=6958 O
ClopidogrelN=6996 O
Dyspnea B-OSE_Labeled_AE
14.2 O
5.5 O
Dizziness B-OSE_Labeled_AE
4.5 O
4.1 O
Diarrhea B-OSE_Labeled_AE
3.3 O
2.5 O
Bradycardia O
In O
a O
Holter O
substudy O
of O
about O
3000 O
patients O
in O
PLATO O
, O
more O
patients O
had O
ventricular B-OSE_Labeled_AE
pauses I-OSE_Labeled_AE
with O
BRILINTA O
( O
6.0 O
% O
) O
than O
with O
clopidogrel O
( O
3.5 O
% O
) O
in O
the O
acute O
phase O
; O
rates O
were O
2.2 O
% O
and O
1.6 O
% O
respectively O
after O
1 O
month O
. O

PLATO O
and O
PEGASUS O
excluded O
patients O
at O
increased O
risk O
of O
bradycardic B-Not_AE_Candidate
events O
( O
e.g. O
, O
patients O
who O
have O
sick B-Not_AE_Candidate
sinus I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
2 O
nd O
or O
3 O
rd O
degree O
AV B-Not_AE_Candidate
block I-Not_AE_Candidate
, O
or O
bradycardic B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
syncope I-Not_AE_Candidate
and O
not O
protected O
with O
a O
pacemaker O
) O
. O

In O
PLATO O
, O
syncope B-OSE_Labeled_AE
, O
pre B-OSE_Labeled_AE
- I-OSE_Labeled_AE
syncope I-OSE_Labeled_AE
and O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
were O
reported O
by O
1.7 O
% O
and O
1.5 O
% O
of O
BRILINTA O
90 O
mg O
and O
clopidogrel O
patients O
, O
respectively O
. O

In O
PEGASUS O
, O
syncope B-OSE_Labeled_AE
was O
reported O
by O
1.2 O
% O
and O
0.9 O
% O
of O
patients O
on O
BRILINTA O
60 O
mg O
and O
aspirin O
alone O
, O
respectively O
. O

Lab O
abnormalities O
Serum O
Uric O
Acid O
: O
In O
PLATO O
, O
serum B-OSE_Labeled_AE
uric I-OSE_Labeled_AE
acid I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
approximately O
0.6 O
mg/dL O
from O
baseline O
on O
BRILINTA O
90 O
mg O
and O
approximately O
0.2 O
mg/dL O
on O
clopidogrel O
. O

The O
difference O
disappeared O
within O
30 O
days O
of O
discontinuing O
treatment O
. O

Reports O
of O
gout B-OSE_Labeled_AE
did O
not O
differ O
between O
treatment O
groups O
in O
PLATO O
( O
0.6 O
% O
in O
each O
group O
) O
. O

In O
PEGASUS O
, O
serum B-OSE_Labeled_AE
uric I-OSE_Labeled_AE
acid I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
approximately O
0.2 O
mg/dL O
from O
baseline O
on O
BRILINTA O
60 O
mg O
and O
no O
elevation O
was O
observed O
on O
aspirin O
alone O
. O

Gout B-OSE_Labeled_AE
occurred O
more O
commonly O
in O
patients O
on O
BRILINTA O
than O
in O
patients O
on O
aspirin O
alone O
( O
1.5 O
% O
,1.1 O
% O
) O
. O

Mean O
serum B-NonOSE_AE
uric I-NonOSE_AE
acid I-NonOSE_AE
concentrations O
decrease I-NonOSE_AE
d O
after O
treatment O
was O
stopped O
. O

Serum O
Creatinine O
: O
In O
PLATO O
, O
a O
> O
50 O
% O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
was O
observed O
in O
7.4 O
% O
of O
patients O
receiving O
BRILINTA O
90 O
mg O
compared O
to O
5.9 O
% O
of O
patients O
receiving O
clopidogrel O
. O

The O
increases O
typically O
did O
not O
progress O
with O
ongoing O
treatment O
and O
often O
decreased O
with O
continued O
therapy O
. O

Evidence O
of O
reversibility O
upon O
discontinuation O
was O
observed O
even O
in O
those O
with O
the O
greatest O
on O
treatment O
increases O
. O

Treatment O
groups O
in O
PLATO O
did O
not O
differ O
for O
renal B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
serious I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
such O
as O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
chronic B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
nephropathy I-OSE_Labeled_AE
, O
or O
oliguria B-OSE_Labeled_AE
. O

In O
PEGASUS O
, O
serum B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
concentration O
increased O
by O
> O
50 O
% O
in O
approximately O
4 O
% O
of O
patients O
receiving O
BRILINTA O
60 O
mg O
, O
similar O
to O
aspirin O
alone O
. O

The O
frequency O
of O
renal B-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
was O
similar O
for O
ticagrelor O
and O
aspirin O
alone O
regardless O
of O
age O
and O
baseline O
renal O
function O
. O

Figure O
1 O
- O
Kaplan-Meier O
Graph O
Figure O
2 O
- O
Bar O
Graph O

